Taiwan · Delayed Price · Currency is TWD CH Biotech R&D Statistics
Total Valuation
CH Biotech R&D has a market cap or net worth of TWD 11.31 billion. The enterprise value is 11.57 billion.
| Market Cap | 11.31B |
| Enterprise Value | 11.57B |
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Aug 21, 2025 |
Share Statistics
CH Biotech R&D has 102.80 million shares outstanding. The number of shares has increased by 3.09% in one year.
| Current Share Class | 102.80M |
| Shares Outstanding | 102.80M |
| Shares Change (YoY) | +3.09% |
| Shares Change (QoQ) | -0.22% |
| Owned by Insiders (%) | 22.87% |
| Owned by Institutions (%) | 0.03% |
| Float | 36.85M |
Valuation Ratios
The trailing PE ratio is 31.18.
| PE Ratio | 31.18 |
| Forward PE | n/a |
| PS Ratio | 6.71 |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.24 |
| P/FCF Ratio | 68.81 |
| P/OCF Ratio | 34.66 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.80, with an EV/FCF ratio of 70.39.
| EV / Earnings | 31.75 |
| EV / Sales | 6.87 |
| EV / EBITDA | 15.80 |
| EV / EBIT | 21.81 |
| EV / FCF | 70.39 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.22 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.21 |
| Debt / FCF | 5.41 |
| Interest Coverage | 33.28 |
Financial Efficiency
Return on equity (ROE) is 13.36% and return on invested capital (ROIC) is 9.34%.
| Return on Equity (ROE) | 13.36% |
| Return on Assets (ROA) | 8.68% |
| Return on Invested Capital (ROIC) | 9.34% |
| Return on Capital Employed (ROCE) | 18.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.44 |
| Inventory Turnover | 3.79 |
Taxes
In the past 12 months, CH Biotech R&D has paid 77.70 million in taxes.
| Income Tax | 77.70M |
| Effective Tax Rate | 17.60% |
Stock Price Statistics
The stock price has increased by +37.16% in the last 52 weeks. The beta is 0.15, so CH Biotech R&D's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +37.16% |
| 50-Day Moving Average | 111.12 |
| 200-Day Moving Average | 88.34 |
| Relative Strength Index (RSI) | 52.28 |
| Average Volume (20 Days) | 64,061 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CH Biotech R&D had revenue of TWD 1.68 billion and earned 364.31 million in profits. Earnings per share was 3.53.
| Revenue | 1.68B |
| Gross Profit | 1.41B |
| Operating Income | 531.90M |
| Pretax Income | 441.51M |
| Net Income | 364.31M |
| EBITDA | 706.48M |
| EBIT | 531.90M |
| Earnings Per Share (EPS) | 3.53 |
Balance Sheet
The company has 629.59 million in cash and 888.66 million in debt, giving a net cash position of -259.08 million or -2.52 per share.
| Cash & Cash Equivalents | 629.59M |
| Total Debt | 888.66M |
| Net Cash | -259.08M |
| Net Cash Per Share | -2.52 |
| Equity (Book Value) | 2.68B |
| Book Value Per Share | 26.05 |
| Working Capital | 198.89M |
Cash Flow
In the last 12 months, operating cash flow was 326.23 million and capital expenditures -161.90 million, giving a free cash flow of 164.33 million.
| Operating Cash Flow | 326.23M |
| Capital Expenditures | -161.90M |
| Free Cash Flow | 164.33M |
| FCF Per Share | 1.60 |
Margins
Gross margin is 83.46%, with operating and profit margins of 31.58% and 21.63%.
| Gross Margin | 83.46% |
| Operating Margin | 31.58% |
| Pretax Margin | 26.21% |
| Profit Margin | 21.63% |
| EBITDA Margin | 41.94% |
| EBIT Margin | 31.58% |
| FCF Margin | 9.76% |
Dividends & Yields
This stock pays an annual dividend of 4.10, which amounts to a dividend yield of 3.73%.
| Dividend Per Share | 4.10 |
| Dividend Yield | 3.73% |
| Dividend Growth (YoY) | 14.21% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 115.69% |
| Buyback Yield | -3.09% |
| Shareholder Yield | 0.64% |
| Earnings Yield | 3.22% |
| FCF Yield | 1.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2022. It was a forward split with a ratio of 1.15.
| Last Split Date | Jul 26, 2022 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
CH Biotech R&D has an Altman Z-Score of 5.58 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.58 |
| Piotroski F-Score | 5 |